Edwards Lifesciences (EW) Competitors

Edwards Lifesciences (NYSE:EW) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Which has more volatility & risk, EW or HSIC?

Edwards Lifesciences has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Does the media prefer EW or HSIC?

In the previous week, Edwards Lifesciences had 2 more articles in the media than Henry Schein. MarketBeat recorded 30 mentions for Edwards Lifesciences and 28 mentions for Henry Schein. Edwards Lifesciences' average media sentiment score of 0.89 beat Henry Schein's score of 0.45 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	17 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Henry Schein	10 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders believe in EW or HSIC?

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.1% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts recommend EW or HSIC?

Edwards Lifesciences presently has a consensus price target of $87.06, suggesting a potential upside of 16.85%. Henry Schein has a consensus price target of $76.67, suggesting a potential upside of 21.73%. Given Henry Schein's higher possible upside, analysts clearly believe Henry Schein is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	1 Sell rating(s)	9 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.68
Henry Schein	0 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Which has stronger earnings and valuation, EW or HSIC?

Edwards Lifesciences has higher earnings, but lower revenue than Henry Schein. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$5.44B	8.04	$4.17B	$6.95	10.72
Henry Schein	$12.67B	0.60	$390M	$3.10	20.32

Is EW or HSIC more profitable?

Edwards Lifesciences has a net margin of 72.96% compared to Henry Schein's net margin of 3.05%. Edwards Lifesciences' return on equity of 15.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	72.96%	15.01%	11.56%
Henry Schein	3.05%	14.36%	5.52%

Summary

Edwards Lifesciences beats Henry Schein on 12 of the 17 factors compared between the two stocks.